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Abstract
Purpose We report a patient with metastatic breast cancer
who received three cycles of high-dose chemotherapy with
cyclophosphamide [1,000 mg/(m2 day)], thiotepa (80 mg/
(m2 day) and carboplatin (dose calculated based on modi-
Wed Calvert formula with 3.25 mg min/ml as daily target
AUC) over 4 days, followed by peripheral blood progenitor
cell support. During the Wrst two cycles the patient concom-
itantly used carbamazepine for the treatment of epilepsy.
Due to severe nausea and vomiting the patient was unable
to ingest carbamazepine; therefore, this was discontinued
after the second cycle.
Methods Blood samples were drawn on 2 days (day 1 and
2, 3 or 4) of each cycle and plasma levels of cyclophospha-
mide, its active metabolite 4-hydroxycyclophosphamide,
thiotepa, its main, active metabolite tepa and carboplatin
were determined.
Results Exposure to 4-hydroxycyclophosphamide and
tepa on day 1 was increased in the presence of carbamaze-
pine (58 and 75%, respectively), while exposure to cyclo-
phosphamide and thiotepa was reduced (40 and 43%,
respectively).
Conclusion Since increased exposure to the active metab-
olites is associated with an increased risk of toxicity, it is
important to be aware of this drug–drug interaction.
Keywords Pharmacokinetics · Cyclophosphamide · 
Thiotepa · Carbamazepine
Introduction
High-dose chemotherapy with autologous peripheral blood
progenitor cell support is used in the treatment of several
haematological malignancies and solid tumours. Although
haematological toxicity is manageable, signiWcant end-
organ toxicity may occur [1]. Interpatient variability in drug
exposure has been shown to correlate with both toxicity and
eVectiveness of high-dose chemotherapy [2]. Since phar-
macokinetics may correlate with outcome, drug–drug inter-
actions between the cytotoxic agents and concomitant
medication may be of clinical importance.
Cyclophosphamide is an inactive prodrug and is
activated by cytochrome P450 to 4-hydroxycyclophos-
phamide. CYP2B6, 2C9, 2C19, 3A4 and 3A5 have been
reported to be involved in the 4-hydroxylation, of which
CYP2B6 is the most important. Furthermore, cyclophos-
phamide shows strong autoinduction, resulting in
increased clearance of the parent compound and
increased formation of its metabolites [3, 4]. Thiotepa is
metabolised by CYP2B6 and CYP3A4 to its main metab-
olite tepa [5]. Thiotepa and tepa have comparable alkyl-
ating activity [6].
Here we report the induction of cyclophosphamide and
thiotepa metabolism due to carbamazepine, resulting in
increased formation of the active metabolites, 4-hydroxycy-
clophosphamide and tepa, respectively.
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Case
A 52-year-old female patient was diagnosed with meta-
static breast cancer. As part of her treatment she received
three cycles of high-dose chemotherapy with autologous
peripheral blood progenitor cell transplantation. This regi-
men consisted of 4 days of chemotherapy with cyclophos-
phamide [1,000 mg/(m2 day)] as 1 h infusion, immediately
followed by carboplatin (dose calculated based on modiWed
Calvert formula with 3.25 mg min/ml as daily target AUC)
as 1 h infusion and thiotepa [80 mg/(m2 day)] divided over
two 30 min infusions 12 h apart. Mesna (500 mg) was
administered six times daily for a total of 36 doses, begin-
ning 1 h prior to the Wrst cyclophosphamide infusion. The
three cycles were given with 4 week intervals. The patient
prophylactically received antibiotics (ciproXoxacin and
Xuconazole orally), starting 4 days before chemotherapy.
Furthermore, during the chemotherapy cycles the patient
received dexamethasone and granisetron. Full details of the
tCTC regimen have been published previously [1].
During the Wrst and second cycles the patient received
carbamazepine (twice daily 200 mg slow release) and viga-
batrin (twice daily 500 mg) orally for the treatment of epi-
lepsy. Due to severe nausea and vomiting, the patient was
unable to ingest carbamazepine. Therefore, after the second
tCTC cycle anti-epileptic treatment was stopped and not
restarted until after the third tCTC cycle.
Pharmacokinetic analysis
For pharmacokinetic analyses, blood samples were col-
lected from a double lumen intravenous catheter inserted in
a subclavian vein. Samples were collected on day 1 and 2, 3
or 4 prior to the start of the infusions at 30 min after the
start of cyclophosphamide infusion (t = 30) and t = 60 (end
of cyclophosphamide infusion), 90, 120 (end of carboplatin
infusion), 150 (end of thiotepa infusion), 180, 210, 285,
390, 660 min and when possible at 24 h. Thiotepa, tepa and
cyclophosphamide were quantiWed with a validated gas
chromatographic assay as described previously. The lower
limits of quantitation for thiotepa, tepa and cyclophospha-
mide were 5, 5 and 50 ng/mL, respectively [7]. 4-Hydroxy-
cyclophosphamide was determined as a semicarbazone
derivative with a previously described and validated high-
performance liquid chromatography assay. The lower limit
of quantitation was 50 ng/mL [8].
A previously published population pharmacokinetic
model of thiotepa (and its metabolite tepa) and cyclophos-
phamide (and its metabolite 4-hydroxycyclophosphamide)
was used for estimating the AUC of all compounds using
Bayesian analysis [9]. The Committee on the Medical
Ethics of the Netherlands Cancer Institute had approved the
protocol and written informed consent was obtained from
the patient.
Results
Plasma concentration versus time curves of cyclophospha-
mide and 4-hydroxycyclophosphamide of all three cycles
are shown in Fig. 1 in combination with the model Wtted
curves. As can be seen in Fig. 1A, cyclophosphamide clear-
ance on day 1 was increased in the presence of carbamaze-
pine, resulting in a lower cyclophosphamide AUC with a
concomitant increase in 4-hydroxycyclophosphamide AUC
(Table 1). Furthermore, in the absence of carbamazepine, a
more pronounced autoinduction of cyclophosphamide was
observed. Cyclophosphamide clearance increased during
the 4 days of cycle 3 (Fig. 1a) and the Cmax of 4-hydroxycy-
clophosphamide was increased on day 4 compared to day 1
(1.9 vs. 0.99 g/mL) of cycle 3 (Fig. 1b). In the presence of
carbamazepine, no autoinduction could be identiWed.
Figure 2 shows the plasma concentration versus time
curves of thiotepa and tepa. Thiotepa clearance was
increased in the presence of carbamazepine (Fig. 2a),
resulting in a lower plasma exposure of thiotepa, with a
concomitant increase in tepa AUC (Table 1).
Tables 1 and 2 show the eVects of carbamazepine on the
AUCs of cyclophosphamide, 4-hydroxycyclophospha-
mide, thiotepa and tepa on day 1 and during the whole
course, respectively. From these tables it can be seen that
the eVects of carbamazepine on cyclophosphamide and
thiotepa pharmacokinetics are more pronounced during the
Wrst day of the course.
The pharmacokinetics of carboplatin were similar during
the three cycles. Besides severe nausea and vomiting during
cycles 2 and 3, no other toxicity was observed during the
three cycles.
Discussion
Here we report an increase in cyclophosphamide and thio-
tepa metabolism caused by co-administration of carbamaz-
epine. Furthermore, in the presence of carbamazepine,
autoinduction of cyclophosphamide is not detectable.
Carbamazepine acts as an anti-convulsant for partial and
grand mal seizures. The activity of a variety of cycto-
chrome P450 enzymes, including CYP1A2, CYP2B,
CYP2C9, CYP2C19 and CYP3A4 is induced by carbamaz-
epine [10–12].
Co-administration with carbamazepine is known to
decrease values of mean peak plasma concentration and
area under the plasma concentration–time curve of many123
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agents. Carbamazepine and other anticonvulsant drugs have
also shown to increase the systemic clearance of chemo-
therapy, resulting in lower eYcacy [13].
The increase in cyclophosphamide and thiotepa clear-
ance observed, may be caused by the induction of CYP
enzymes 2B6 and 3A4 which are mainly involved in cyclo-
phosphamide and thiotepa metabolism. The absence of
Fig. 1 Plasma concentration versus time curves of a cyclophosphamide (CP 1,780 mg) and b 4-hydroxycyclophosphamide (4OHCP) in three
high-dose tCTC chemotherapy cycles, the Wrst and second cycles with carbamazepine and the third cycle without carbamazepine123
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bamazepine is probably due to the metabolising enzymes
already being induced by carbamazepine.
The eVect of carbamazepine was more pronounced dur-
ing the Wrst day of the course. The overall AUC of the sev-
eral compounds was only moderately aVected by
carbamazepine. This could be due to cyclophosphamide
also being an inducer of CYP2B6 and CYP3A4, thereby
increasing its own metabolism and the metabolism of thio-
tepa, if carbamazepine is absent, and therefore producing
the same eVect as carbamazepine [9].
For both cyclophosphamide and thiotepa, studies have
demonstrated that alterations in liver CYP enzyme compo-
sition and activity have a major impact on the pharmacoki-
netics of these agents [14–17]. Xie et al. [18] found one
patient with a very high 4-hydroxylation activity in their
study into the pharmacogenetics of cyclophosphamide in
patients with haematological malignancies. DiVerent from
the other patients, this patient was treated with carbamaze-
pine. No other reports have been published, to our knowl-
edge, on the induction of cyclophosphamide and thiotepa
metabolism by carbamazepine.
The patient in our report also received vigabatrin. It is
unlikely that vigabatrin caused this interaction since viga-
batrin does not induce the hepatic cytochrome P450
enzyme system [19].
This report shows that carbamazepine induces the
metabolism of cyclophosphamide and thiotepa. This inter-
action will predominantly be important in single-dose
administrations. Increases in exposure to the active metabo-
lites could lead to increased toxicity.
Since the eVect of changes in enzyme activity can vary
substantially between patients and because of the unpre-
dictability of the magnitude of this eVect, it is recom-
mended that carbamazepine is used with precaution with
cyclophosphamide and thiotepa.
Table 1 EVect of carbamaze-
pine on the AUC of day 1 of 
cyclophosphamide, thiotepa and 
metabolites
Compounds Cycles 1 and 2 with 
carbamazepine mean AUC 
day 1 (AUC cycle 1–AUC 
cycle 2)
Cycle 3 without 
carbamazepine 
AUC day 1 
DiVerence 
(%)
Cyclophosphamide 0.57 (0.59–0.56) mM h 0.95 mM h ¡40
4-Hydroxycyclophosphamide 31.2 (31.8–30.5) M h 19.7 M h 58
Thiotepa 11.8 (12.3–11.4) M h 20.6 M h ¡43
Tepa 50.3 (50.7–50.0) M h 28.8 M h 75
Fig. 2 Plasma concentration versus time curves of a thiotepa (TT
70 mg) and b tepa (T), in three high-dose tCTC chemotherapy cycles;
Wlled diamond, the Wrst cycle (with carbamazepine); Wlled square, the
second cycle (with carbamazepine); and open triangle, the third cycle
(without carbamazepine)
Table 2 EVect of carbamaze-
pine on the overall AUC of 
cyclophosphamide, thiotepa and 
metabolites
Compounds Cycles 1 and 2 with 
carbamazepine mean AUC 
(AUC cycle 1–AUC cycle 2)




Cyclophosphamide 2.5 (2.7–2.3) mM h 3.1 mM h ¡19
4-Hydroxycyclophosphamide 122 (123–120) M h 95 M h 28
Thiotepa 46.4 (48.0–44.8) M h 94.0 M h ¡51
Tepa 233 (228–239) M h 191 M h 22123
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phamide and thiotepa metabolism by phenytoin was
described [20]. When seizure control is necessary in
patients receiving concomitant chemotherapy, drugs that do
not inXuence the hepatic cytochrome P450 enzyme system
(gabapentin and  levetiracetam) are to be preferred [21].
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